Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there a chance for another +300% day tomorrow? Would be exciting since float is so low.
What’s up with that lawsuit against LVVV? Someone made a comment regarding it on LVVV’s tweet today. Is there any validity? What’s the chance of that getting thrown out?
I strongly agree.
Touché
Best regards,
SeaSailor
I believe everyone needs to settle down with the assumptions/reading into things. This presentation doesn’t seem like a formal vote with city council regarding if Coachella will accept the process being pitched. I believe it will be an informative session to explain how they have a solution that can prevent a lot of upcoming potential issues when Jul 2018 rolls around.
Best regards,
SeaSailor
Good afternoon,
I had a pleasant weekend exploring the city of Coachella and getting the opportunity to speak with some of the locals. The sentiment regarding the industrialization of Marijuana in the valley (Palm Springs & Coachella) seemed to be positive. Tourism drives their local economy almost entirely around the months of November-May roughly. The individuals I spoke with mentioned that their concerns are with the city having the necessary funds to pay teachers a decent wage to live. They hope that the extra taxes from legalization of Marijuana along with the many industrialization projects regarding cultivation will help the city.
Below are some links to some of the photos I took along with a video of me driving southbound on Enterprise Way.
Click_For_YouTube_Video
Click_For_Picture_1
Click_For_Picture_2
Click_For_Picture_3
Click_For_Picture_4
Good morning all,
Wanted to inform anyone interested that I am taking a weekend trip to Coachella for the sole purpose of verifying the pod locations as well as the city approved 33-acre business center that should be getting built. I believe Coachella Brands Inc., are the ones that have pushed for that effort.
Please let me know if there any specific locations to check up on since Google Earth hasn’t updated for some time.
Best regards,
Seasailor
Out of curiosity, has anyone visited Avenue 48 recently? I’m extremely interested to see how construction is coming along. I know Cultivation Technologies Inc, is leading the effort. Would love to see the progress they have made especially since they secured desired funding for the necessary substation power from IID (Jan 2018).
Best regards,
Seasailor
Thanks for the info!
I am curious to see if anyone could find information about “American Grow Products Inc”. I am having a difficult time finding information about that company.
Best regards,
Seasailor
Kizersosae,
My student loans would have been paid off had I done the same thing. I’m in a different industry now but wish everyone the best. Take a look at the stocks involved in the Cali MJ stocks. I feel it will get quite interesting within the year.
Wish you all the best! Stay safe as a cop in Pittsburgh. I am from Pittsburgh, “Go Steelers!”. Live in Arizona now however will always miss my city.
Best regards,
Sea sailor
Great link! Thank you.
I’ve been following this for some time. Look forward for this stock to mature into what the Canadian MJ stocks have become in less than 2 years.
DREAM BIG, I don't meant rain on your parade...Nelson Research (basically spam) is nothing more than an algorithm that auto publishes articles, and aren't very informative nor useful.
Kizersozae, to answer your question I believe the article below may have been the data they were referring too with respect to Prodetoxone clinical research data.
Title: "Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant"
Authors: George E. Woody, M.D. (University of Pennsylvania), and many more (too lazy to type them up)
Published: September 2016
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156574/
Snippet From Results Section of Article:
Recruitment, Demographics and Outcomes:
Patients were recruited from 2006 to 2008; 358 patients were asked if they were interested, 309 gave informed consent and 306 met study entrance criteria, completed baseline assessments and were randomized to one of the three groups resulting in 102/group. Mean age was 28.2±4.2 years (M±SD; 17- 40); average years dependent on heroin was 8.0±3.9 (M±SD); and use of alcohol and other drugs was minimal. There were no significant between group differences at baseline.
Treatment retention without relapsing, opiate urine test results, outcomes according to the Addiction Severity Index, and HIV risk behaviors all favored the implant group; details are in the primary outcome paper (Krupitsky et al, 2012).
Funded By: National Institute on Drug Abuse grants: 1-R01-DA-017317 and KO5 DA-17009 supported this study.
My Summary: BICX could have bought this data back in 2016.
------------
Title: "Current Progress On Opioid Treatment"
Author: George E. Woody, M.D. (Name is looks familiar)
Published: May 2017
Link: https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2016.16121398
My Summary: This is a good read to understand where we stand with the available opioid treatments. I wish I had access to read the entire editorial, however I don't :(
"Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence"
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614358/
Funding/Support: This study was supported by grants 1-R01-DA-017317 and KO5 DA-17009 from the National Institute on Drug Abuse (Dr Woody). Fidelity Capital provided naltrexone implants at reduced cost and placebo implants at no cost. The Zambon Group provided oral naltrexone at reduced cost.
"Methadone is a schedule I drug in Russia, and the Ministry of Health has not accepted Western data on the benefits of agonist maintenance therapy. This approach is similar in many ways to the United States from the mid- 1920s to late 1960s, when physicians could lose their licenses or be arrested and jailed if they used opioids to treat opioid addicts. However, unlike the United States during those years, Russia has committed significant resources to detoxification and residential treatment. For example, state-supported alcohol and drug treatment is provided in 138 dispensaries (115 of which have inpatient units) and 12 addiction hospitals with more than 25 000 beds in total and from 50 to 2000 beds per hospital depending on the region. In addition, several hundred commercial and nongovernmental organizations and more than 5600 psychiatrist-narcologists work in the addiction field (Evgenia Koshkina, MD, PhD, personal communication, September 2011). This treatment is readily available, as seen in the Table, where study patients averaged 4 to 5 prior treatment episodes."
NOTE at the bottom of the page before the references, look at the paid consultant's company:
"Financial Disclosure: Dr Krupitsky is a paid consultant to Alkermes, and Alkermes is providing extendedrelease injectable naltrexone for a study in which Dr Woody is an investigator."
I google, “FDA Opioid Crisis” every day to see if Scott Gottlieb releases any new PR with respect to strategy and thoughts from the agency. Then I google, “BICX” at least once an hour to keep up with the stock price. Lastly, I’ll check up on our competitors to stay aware of what’s going on around us.
By the way, looking at our competition. I almost fell out of my chair with excitement reading Braeburn Pharmaceuticals received a CRL from the FDA (chuckle).
PR Link: titan-in-discussions-with-braeburn-regarding-us-probuphine-commercialization
Here’s the link, so you can click on it: Link_To_Research_Paper
If anyone would like to take the time to read a University of Pennsylvania research paper published May 2006 analyzing the aspects of using Naltrexone in lieu of incarceration.
Link to research PDF: goo.gl/SYWzHi
Apologies for horrendous grammar. iPhone didn’t pick up shit....
Have a good weekend,
Seasailor
I am disappointed (I’m sure Brady is as well) that we have to wait until Jan 2018 for the pre-ind meeting. I’m aware of all the federal grant funds that were awarded to the states. I’m not so sure how the states will appropriate those funds...if any to industry/when.
Next, we WILL have to go through trials, most of the ongoing concerns for Naltrexone implant is the lack of data to support how one will do. I doubt we will be able to skip trials, but hopefully we can skip a lot of the requirements and go straight into a Phase 3 study, to just get this implant of Naltrexone approved. So I expect a study that is hopefully funded by either the grants or NIH, which will evaluate the safety and efficacy for long term extended release (6 months or so) of Naltrexone.
This approach isn’t new, since Braeburn and Titan has to go through the same thing with Proburphine. I just hope we don’t RS (the way Titan did to get on NASDAQ before they got their implant approved). I hope we get some form of funding from somewhere to keep lights on like TEB mentioned sometime ago.
At the moment, Alkemeres has a ton of cash on hand so they could very well, possibly buy us out. Unfortunately, we don’t lose a threat to their current primarily revenue source (Vivitrol). We need to cut into their profit margins for that to become a reality. There’s too much uncertainty for me to accurately make an estimated SP for upcoming months. I do believe if FDA grants fast track or some form of an expedited review, and we use grant funding from somewhere to pay for those trials. We’ll be in a good position.
With regards to an IND application cost, I believe someone will jump in to cover those costs otherwise we will have to issue more shares to keep moving forward.
I hope in 6-8 months we will be trading @ 0.5
Could anyone provide some color regarding Alkermes (ALKS) litigation for case: IPR2016-01096. How could this impact their company if not ruled in their favor? Next question would be how it could possibly benefit BICX.
"On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased viscosity. The ’061 patent is owned by Alkermes Pharma Ireland, Ltd. and Alkermes Controlled Therapeutics, Inc. (“Alkermes”), and is listed in the Orange Book in connection with formulations of risperidone (Janssen Pharmaceuticals, Inc.), naltrexone (Alkermes, Inc.), and synthetic exenatide (AstraZeneca AB). Luye Pharma Group Ltd. (“Luye”) filed a pair of petitions challenging all but three of the twenty-three claims in the ’061 patent. In the case of IPR2016-01096, the PTAB instituted an IPR as to all challenged claims on various obviousness grounds."
Quote Link:
http://www.ptablitigationblog.com/inherent-obviousness-artisans-need-not-recognize-latent-properties-to-challenge-claims/
Case IPR2016-01096:
http://www.ptablitigationblog.com/wp-content/uploads/2016/12/IPR2016-01096.pdf